市場調查報告書

滑膜肉瘤(SS)- 市場洞察、流行病學、市場預測 2028年

Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 773910
出版日期 內容資訊 英文 151 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
滑膜肉瘤(SS)- 市場洞察、流行病學、市場預測 2028年 Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年11月01日內容資訊: 英文 151 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的滑膜肉瘤(SS)的2017年的罹患數為2,091人,同年的市場規模估算為約5,943萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的滑膜肉瘤(SS)市場調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,以整體及各國的市場趨勢,流行病學的預測,市場規模,部位、年齡、性別、各病期的罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 滑膜肉瘤(SS)市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 2次類型
  • 原因和危險因素
  • 症狀
  • 病理生理學
  • 遺傳的方面
  • 惡性度分類和病期分類
  • 診斷
  • 預後
  • 滑膜肉瘤的轉移性生物標記

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的總罹患數
  • 主要7個國家的診斷罹患數

第5章 滑膜肉瘤(SS)的流行病學:各國

  • 美國
    • 假設和根據
    • 總罹患數
    • 診斷數
    • 診斷罹患數:各部位
    • 診斷罹患數:性別
    • 診斷罹患數:各年齡
    • 診斷罹患數:各病期
  • 歐盟5國
    • 德國
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷罹患數:各部位
      • 診斷罹患數:性別
      • 診斷罹患數:各年齡
      • 診斷罹患數:各病期
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和根據
    • 總罹患數
    • 診斷數
    • 診斷罹患數:各部位
    • 診斷罹患數:性別
    • 診斷罹患數:各年齡
    • 診斷罹患數:各病期

第6章 治療及管理的指南

  • 歐洲醫學腫瘤學會 - 稀少成人固體癌臨床診療指南(ESMO-EURACAN-CGP)
  • 軟組織肉瘤的管理相關英國家指南
  • 把軟組織肉瘤的診斷和治療的改善作為目的NICE指南

第7章 未滿足需求

第8章 已上市治療藥

  • Yondelis (Trabectadin) :PharmaMar
    • 產品概要
    • 法規的里程碑
    • 製造
    • 許可證
    • 專利
    • 安全性和有效性
    • 產品簡介
  • Pazopanib:Novartis
    • 作用機制
    • 產品開發趨勢

第9章 新藥

  • Tazemetostat:Yondelis
    • 產品概要
    • 產品開發趨勢
    • 臨床開發
    • 臨床實驗資訊
    • 產品簡介
  • ADP-A2M4:Adaptimmune
  • Anlotinib(AL3818):Advenchen Laboratories

第10章 主要7個國家的滑膜肉瘤(SS)市場分析

  • 主要調查結果
  • 主要7個國家的市場規模

第11章 美國的滑膜肉瘤(SS)市場預測

  • 市場規模
    • 整體市場規模
    • 市場規模:各選擇治療藥物
    • 市場規模:各治療藥物

第12章 歐盟5國的滑膜肉瘤(SS)市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各選擇治療藥物
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本的滑膜肉瘤(SS)市場預測

  • 市場規模
    • 整體市場規模
    • 市場規模:各選擇治療藥物
    • 市場規模:各治療藥物

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

  • 調查方法

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0472

DelveInsight's 'Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Synovial Sarcoma from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Synovial Sarcoma (SS) - Disease Understanding and Treatment Algorithm

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8-10% of all soft tissue sarcomas (STS). Synovial Sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated and can affect patients of any age, although it is most common in adolescents and adults younger than 30 years of age. In the adolescent patient population, SS is considered the most common sarcoma subtype. The exact underlying cause of synovial sarcoma is poorly understood. However, studies show that a certain genetic change is identified in more than maximum number of cases.

The DelveInsight Synovial Sarcoma (SS) market report gives the thorough understanding of the Synovial Sarcoma by including details such as disease definition, classification, symptoms, genetics factors, risk factors, grading and staging, biomarkers, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Synovial Sarcoma in the US, Europe and Japan.

Synovial Sarcoma Epidemiology

The Synovial Sarcoma (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases , diagnosed incident cases, Site-specific incidence, gender-specific incidence, age-specific incidence, stage-specific incidence) scenario of synovial sarcoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Synovial Sarcoma (SS) in 7 MM was found to be 2091 in the year 2017.

Synovial Sarcoma Drug Chapters

This segment of the Synovial Sarcoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Surgery remains the cornerstone of treatment and the only curative locoregional approach of localized resectable Soft Tissue Sarcoma including Synovial Sarcoma cases. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. Chemotherapy forms the first line of defense to treat most metastatic sarcomas with SS being no exception. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response.

Synovial Sarcoma Market Outlook

The Synovial Sarcoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Synovial Sarcoma in 7MM was found to be USD 59.43 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Synovial Sarcoma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Synovial Sarcoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Synovial Sarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Synovial Sarcoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Synovial Sarcoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Synovial Sarcoma market
  • Organize sales and marketing efforts by identifying the best opportunities for A Synovial Sarcoma market
  • To understand the future market competition in the Synovial Sarcoma market.

Table of Contents

1. Key Insights

2. Synovial Sarcoma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Synovial Sarcoma Market in 2017
  • 2.2. Market Share (%) Distribution of Synovial Sarcoma Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes
  • 3.3. Causes and risk factors
  • 3.4. Symptoms
  • 3.5. Pathophysiology
  • 3.6. Genetic aspect of synovial sarcoma
  • 3.7. Grading and staging of soft tissue sarcoma
  • 3.8. Diagnosis
  • 3.9. Prognosis
  • 3.10. Metastatic biomarkers in Synovial Sarcoma

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Incident Patient Population of Synovial Sarcoma
  • 4.3. 7MM Diagnosed Incident Patient Population of Synovial Sarcoma

5. Country Wise-Epidemiology of Synovial Sarcoma

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Incident Cases of SS
    • 5.1.3. Diagnosed Incidence of SS
    • 5.1.4. Site Specific Diagnose incident cases of SS
    • 5.1.5. Gender Specific diagnosed incident cases of SS
    • 5.1.6. Age Specific diagnosed incident cases of SS
    • 5.1.7. Stage Specific diagnosed Incident of cases of SS
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Incident Cases of SS
    • 5.3.2. Diagnosed Incidence of SS
    • 5.3.3. Site Specific diagnosed incident cases of SS
    • 5.3.4. Gender Specific diagnosed incident cases of SS
    • 5.3.5. Age Specific diagnosed incident cases of SS
    • 5.3.6. Stage Specific diagnosed Incident of cases of SS
  • 5.4. France
    • 5.4.1. Total Incident Cases of SS
    • 5.4.2. Diagnosed Incidence of SS
    • 5.4.3. Site Specific diagnosed incident cases of SS
    • 5.4.4. Gender Specific diagnosed incident cases of SS
    • 5.4.5. Age Specific diagnosed incident cases of SS
    • 5.4.6. Stage Specific diagnosed Incident of cases of SS
  • 5.5. Italy
    • 5.5.1. Total Incident Cases of SS
    • 5.5.2. Diagnosed Incidence of SS
    • 5.5.3. Site Specific diagnosed incident cases of SS
    • 5.5.4. Gender Specific diagnosed incident cases of SS
    • 5.5.5. Age Specific diagnosed incident cases of SS
    • 5.5.6. Stage Specific diagnosed Incident of cases of SS
  • 5.6. Spain
    • 5.6.1. Total Incident Cases of SS
    • 5.6.2. Diagnosed Incidence of SS
    • 5.6.3. Site Specific diagnosed incident cases of SS
    • 5.6.4. Gender Specific diagnosed incident cases of SS
    • 5.6.5. Age Specific diagnosed incident cases of SS
    • 5.6.6. Stage Specific diagnosed Incident of cases of SS
  • 5.7. United Kingdom
    • 5.7.1. Total Incident Cases of SS
    • 5.7.2. Diagnosed Incidence of SS
    • 5.7.3. Site Specific diagnosed incident cases of SS
    • 5.7.4. Gender Specific incident cases of SS
    • 5.7.5. Age Specific diagnosed incident cases of SS
    • 5.7.6. Stage Specific diagnosed Incident of cases of SS
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Incident Cases of SS
    • 5.8.3. Diagnosed Incidence of SS
    • 5.8.4. Site Specific diagnosed incident cases of SS
    • 5.8.5. Gender Specific diagnosed incident cases of SS
    • 5.8.6. Age Specific diagnosed incident cases of SS
    • 5.8.7. Stage Specific diagnosed Incident of cases of SS

6. Guidelines for Treatment/ Management of Soft-Tissue Sarcoma

  • 6.1. European Society for Medical Oncology- European Reference Network for rare adult solid cancers Clinical Practice Guidelines (ESMO-EURACAN-CGP): for Soft-Tissue Sarcoma
  • 6.2. UK Guidelines for Management of Soft-tissue Sarcomas
  • 6.3. NICE Guidelines for Improving Diagnosis and Treatment of Soft-Tissue Sarcoma

7. Unmet needs

8. Marketed Drugs

  • 8.1. Yondelis (Trabectadin) - PharmaMar
    • 8.1.1. Product description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Manufacturing
    • 8.1.4. Licensing
    • 8.1.5. Patent
    • 8.1.6. Safety and Efficacy
    • 8.1.7. Product Profile
  • 8.2. Pazopanib: Novartis
    • 8.2.1. Product description
    • 8.2.2. Mechanism of action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Product Development Activities
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile

9. Emerging drugs

  • 9.1. Tazemetostat: Yondelis
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical development
    • 9.1.4. Clinical Trials Information
    • 9.1.5. Product Profile
  • 9.2. ADP-A2M4: Adaptimmune
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
    • 9.2.4. Clinical Trials Information
    • 9.2.5. Product Profile
  • 9.3. Anlotinib (AL3818): Advenchen Laboratories
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
    • 9.3.4. Clinical Trials Information
    • 9.3.5. Product Profile

10. Synovial Sarcoma: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Synovial Sarcoma in 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market Size of Synovial Sarcoma
    • 11.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 11.1.3. Total Market Size of Synovial Sarcoma by therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market Size of Synovial Sarcoma
    • 12.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.1.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Synovial Sarcoma
    • 12.2.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.2.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Synovial Sarcoma
    • 12.3.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.3.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Synovial Sarcoma
    • 12.4.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.4.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Synovial Sarcoma
    • 12.5.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.5.3. Total Market Size of Synovial Sarcoma by therapies

13. Japan: Market Outlook

  • 13.1. Japan market Size
    • 13.1.1. Total Market Size of Synovial Sarcoma
    • 13.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 13.1.3. Total Market Size of Synovial Sarcoma by therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: Total Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 2: Total Diagnosed Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 3: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Table 4: Diagnosed Incidence of SS in the United States (2017-2028)
  • Table 5: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Table 6: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 7: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 8: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Table 9: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Table 10: Diagnosed Incidence of SS in Germany (2017-2028)
  • Table 11: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 12: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 13: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 14: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Table 15: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Table 16: Diagnosed Incidence of SS in France (2017-2028)
  • Table 17: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 18: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 19: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 20: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Table 21: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Table 22: Diagnosed Incidence of SS in Italy (2017-2028)
  • Table 23: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 24: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 25: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 26: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Table 27: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Table 28: Diagnosed Incidence of SS in Spain (2017-2028)
  • Table 29: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 30: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 31: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 32: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Table 33: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Table 34: Diagnosed Incidence of SS in the UK (2017-2028)
  • Table 35: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 36: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 37: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 38: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Table 39: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Table 40: Diagnosed Incidence of SS in Japan (2017-2028)
  • Table 41: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 42: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 43: Age Specific incident cases of SS in Japan (2017-2028)
  • Table 44: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Table 45: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Table 46: Total Market Size of Synovial Sarcoma in the United States, USD Million (2017-2028)
  • Table 47: Total Market Size of Synovial Sarcoma by line of therapies in the United States, in USD Million (2017-2028)
  • Table 48: Total Market Size of Synovial Sarcoma by therapies in the United States, USD Million (2017-2028)
  • Table 49: Total Market Size of Synovial Sarcoma in Germany, USD Million (2017-2028)
  • Table 50: Total Market Size of Synovial Sarcoma by line of therapies in Germany, in USD Million (2017-2028)
  • Table 51: Total Market Size of Synovial Sarcoma by therapies in Germany, USD Million (2017-2028)
  • Table 52: Total Market Size of Synovial Sarcoma in France, USD Million (2017-2028)
  • Table 53: Total Market Size of Synovial Sarcoma by line of therapies in France, in USD Million (2017-2028)
  • Table 54: Total Market Size of Synovial Sarcoma by therapies in France, USD Million (2017-2028)
  • Table 55: Total Market Size of Synovial Sarcoma in Italy, USD Million (2017-2028)
  • Table 56: Total Market Size of Synovial Sarcoma by line of therapies in Italy, in USD Million (2017-2028)
  • Table 57: Total Market Size of Synovial Sarcoma by therapies in Italy, USD Million (2017-2028)
  • Table 58: Total Market Size of Synovial Sarcoma in Spain, USD Million (2017-2028)
  • Table 59: Total Market Size of Synovial Sarcoma by line of therapies in Spain, in USD Million (2017-2028)
  • Table 60: Total Market Size of Synovial Sarcoma by therapies in Spain, USD Million (2017-2028)
  • Table 61: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Million (2017-2028)
  • Table 62: Total Market Size of Synovial Sarcoma by line of therapies in The United Kingdom, in USD Million (2017-2028)
  • Table 63: Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Million (2017-2028)
  • Table 64: Total Market Size of Synovial Sarcoma in Japan, USD Million (2017-2028)
  • Table 65: Total Market Size of Synovial Sarcoma by line of therapies in Japan, in USD Million (2017-2028)
  • Table 66: Total Market Size of Synovial Sarcoma by therapies in Japan, USD Million (2017-2028)

List of Figures

  • Figure 1: Subtypes of Synovial Sarcoma
  • Figure 2: Risk factors associated with Synovial Sarcoma
  • Figure 3: SYT-SSX fusion
  • Figure 4: Protein interaction domains involved in synovial sarcoma
  • Figure 5: Relationship between SS18, SS18-SSX and the BAF complex
  • Figure 6: Genomic changes associated with Synovial Sarcoma
  • Figure 7: Biomarkers in Synovial Sarcoma
  • Figure 8: Total Incident Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 9: Total Diagnosed Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 10: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Figure 11: Diagnosed Incidence of SS in the United States (2017-2028)
  • Figure 12: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Figure 13: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 14: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 15: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Figure 16: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Figure 17: Diagnosed Incidence of SS in Germany (2017-2028)
  • Figure 18: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 19: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 20: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 21: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Figure 22: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Figure 23: Diagnosed Incidence of SS in France (2017-2028)
  • Figure 24: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 25: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 26: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 27: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Figure 28: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Figure 29: Diagnosed Incidence of SS in Italy (2017-2028)
  • Figure 30: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 31: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 32: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 33: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Figure 34: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Figure 35: Diagnosed Incidence of SS in Spain (2017-2028)
  • Figure 36: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 37: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 38: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 39: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Figure 40: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Figure 41: Diagnosed Incidence of SS in the UK (2017-2028)
  • Figure 42: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 43: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 44: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 45: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Figure 46: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Figure 47: Diagnosed Incidence of SS in Japan (2017-2028)
  • Figure 48: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 49: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 50: Age Specific incident cases of SS in Japan (2017-2028)
  • Figure 51: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Figure 52: The Multi-disciplinary judgment approach
  • Figure 53: Management of Localized clinically resectable STSs
  • Figure 54: Synovial Sarcoma unmet needs
  • Figure 55: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Figure 56: Total Market Size of Synovial Sarcoma in the United States, USD Millions (2017-2028)
  • Figure 57: Total Market Size of Synovial Sarcoma by line of therapies the United States, in USD Million (2017-2028)
  • Figure 58:Total Market Size of Synovial Sarcoma by therapies in the United States, USD Millions (2017-2028)
  • Figure 59: Total Market Size of Synovial Sarcoma in Germany, USD Millions (2017-2028)
  • Figure 60: Total Market Size of Synovial Sarcoma by line of therapies Germany, in USD Million (2017-2028)
  • Figure 61:Total Market Size of Synovial Sarcoma by therapies in Germany, USD Millions (2017-2028)
  • Figure 62: Total Market Size of Synovial Sarcoma in France, USD Millions (2017-2028)
  • Figure 63: Total Market Size of Synovial Sarcoma by line of therapies France, in USD Million (2017-2028)
  • Figure 64:Total Market Size of Synovial Sarcoma by therapies in France, USD Millions (2017-2028)
  • Figure 65: Total Market Size of Synovial Sarcoma in Italy, USD Millions (2017-2028)
  • Figure 66: Total Market Size of Synovial Sarcoma by line of therapies Italy, in USD Million (2017-2028)
  • Figure 67:Total Market Size of Synovial Sarcoma by therapies in Italy, USD Millions (2017-2028)
  • Figure 68: Total Market Size of Synovial Sarcoma in Spain, USD Millions (2017-2028)
  • Figure 69: Total Market Size of Synovial Sarcoma by line of therapies Spain, in USD Million (2017-2028)
  • Figure 70:Total Market Size of Synovial Sarcoma by therapies in Spain, USD Millions (2017-2028)
  • Figure 71: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Millions (2017-2028)
  • Figure 72: Total Market Size of Synovial Sarcoma by line of therapies The United Kingdom, in USD Million (2017-2028)
  • Figure 73:Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Millions (2017-2028)
  • Figure 74: Total Market Size of Synovial Sarcoma in Japan, USD Millions (2017-2028)
  • Figure 75: Total Market Size of Synovial Sarcoma by line of therapies Japan, in USD Million (2017-2028)
  • Figure 76:Total Market Size of Synovial Sarcoma by therapies in Japan, USD Millions (2017-2028)
  • Figure 77: Synovial Sarcoma market drivers
  • Figure 78: Synovial Sarcoma market barriers
Back to Top